NEW YORK, March 6 - Orchid BioSciences on Wednesday said it earned approximately $2.5 million after money-management firm Robertson Stephens exercised its over-allotment option to purchase an additional 1 million shares of the company.
Registering provides access to this and other free content.
Already have an account?Login Now.
An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.
Research funding in Canada is to remain mostly the same, ScienceInsider reports.
In Science this week: random DNA replication errors play role in cancer, and more.
The Bill and Melinda Gates Foundation embarks on an open-access publishing path.